Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

By Sievers Eric L  

Expert Opinion on Biological Therapy, Vol. 1, Iss. 5, 2001-09 ,pp. : 893-901

Informa Healthcare

Access to resources Recommend Favorite

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia

By Hütter Marie-Luise   Schlenk Richard F  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 10, 2011-10 ,pp. : 1369-1380

Informa Healthcare

Access to resources Recommend Favorite

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

By Breccia Massimo   Lo-Coco Francesco  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 2, 2011-02 ,pp. : 225-234

Informa Healthcare

Access to resources Recommend Favorite

Antibody-based treatment of acute myeloid leukaemia

By Mulford Deborah A   Jurcic Joseph G  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 1, 2004-01 ,pp. : 95-105

Informa Healthcare

Access to resources Recommend Favorite

Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?

By Meiners Petra M   Vissink Arjan   Kallenberg Cees GM   Kroese Frans GM   Bootsma Hendrika  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 10, 2011-10 ,pp. : 1381-1394

Informa Healthcare

Access to resources Recommend Favorite